Loading...
*  Percutaneous coronary intervention
... at risk-a treatment with paclitaxel-eluting balloon followed by BMS may reduce the incidence of coronary restenosis or ... Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat narrowing (stenosis) of the coronary ... Coronary angioplasty, also known as percutaneous transluminal coronary angioplasty (PTCA), because it is done through the skin ... 2012). "Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic ...
*  Angioplasty
... and be more prone to restenosis, relative to vascular bypass or coronary artery bypass grafting. After angioplasty, most ... A percutaneous coronary intervention is first performed. A PCI used with stable coronary artery disease reduces chest pain, but ... coronary arteries of the heart found in coronary heart disease. These stenotic segments are due to the buildup of cholesterol- ... The first coronary angioplasty with a drug delivery stents system was performed by Luis de la Fuente, at de Instituto Argentino ...
*  Restenosis
For instance, a coronary stent patient who develops restenosis may experience recurrent chest pain (angina) or suffer from a ... This is usually restenosis of an artery, or other blood vessel, or possibly a vessel within an organ. Restenosis is a common ... Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually ... When a stent is used and restenosis occurs, this is called in-stent restenosis or ISR. If it occurs following balloon ...
*  Cardiology in Review
"Prevention of Coronary Restenosis". Caridology in Review. 7 (4): 219-231. doi:10.1097/00045415-199907000-00014. PMID 10423674. ...
*  Alan Heldman
2001). "Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis". ... His clinical interests include high risk and complex coronary intervention, treatment of hypertrophic cardiomyopathy, including ... could prevent restenosis. His research interests include delivery of stem cells to the heart for repair of myocardial ...
*  Paclitaxel
... is used as an antiproliferative agent for the prevention of restenosis (recurrent narrowing) of coronary and ... 2001). "Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis" (PDF). ... Paclitaxel drug eluting coated stents for coronary artery placement are sold under the trade name Taxus by Boston Scientific in ...
*  Daljeet Singh Gambhir
... he is known to have established a radiation therapy department at the hospital for the treatment of coronary restenosis. Later ... Gambhir, known to have specialized in non-surgical coronary interventional techniques, is reported to have performed over ... he is reported to have performed over 10,000 coronary interventions. The Government of India awarded him the fourth highest ...
*  Interleukin 36 receptor antagonist
2004). "IL-1 cluster genes and occurrence of post-percutaneous transluminal coronary angioplasty restenosis: a prospective, ...
*  Zotarolimus
... development of thrombosis which impedes the efficiency of coronary stents, haemorrhagic and restenosis complications are ... Restenosis is typically described by clinical trials in a binary approach, otherwise known as "binary restenosis" or just " ... The first human coronary stent implantation was first performed in 1986 by Puel et al. However, there are complications ... Coronary stents reduce early complications and improve late clinical outcomes in patients needing interventional cardiology. ...
*  Bioresorbable stent
February 1988). "Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative ... 15 March 2008). "A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery ... 2008). "A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions ( ... 14 March 2009). "A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple ...
*  MTOR inhibitors
Since then, rapamycin has also shown to be effective for preventing coronary artery re-stenosis and for the treatment of ... In 2003, the U.S. Food and Drug Administration approved sirolimus-eluting coronary stents, which are used in patients with ... "CYPHER™ Sirolimus-eluting Coronary Stent - P020026". Food and Drug Administration. Retrieved 25 September 2012. "Torisel". ... narrowing of coronary arteries, or so-called atherosclerosis. Recently rapamycin has shown effective in the inhibition of ...
*  MMP3
"Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis". The American ... Lopid Coronary Angiography Trial". Atherosclerosis. 139 (1): 49-56. doi:10.1016/S0021-9150(98)00053-7. PMID 9699891. de Maat MP ... such as progressive coronary atherosclerosis. The -1171 5A/6A variant has also been associated with congenital anomalies such ... "Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which ...
*  Endothelial dysfunction
"Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis". ... "Endothelial dysfunction and coronary artery disease". Coronary Artery Disease. 25 (8): 713-724. doi:10.1097/mca. ... "Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: ... Testing can also take place in the coronary arteries themselves but this is invasive and not normally conducted unless there is ...
*  Health effects of tobacco
"Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox ... decrease coronary flow velocity reserves, and reduce heart rate variability, potentially increasing the risk of heart attack[ ... in hospital admissions for acute coronary syndrome. 67% of the decrease occurred in non-smokers. A study published in the ... "Smoke-free legislation and hospitalizations for acute coronary syndrome". The New England Journal of Medicine. 359 (5): 482-491 ...
*  Sean P. Pinney
Anti-HLA antibodies are associated with restenosis after percutaneous coronary intervention for cardiac allograft vasculopathy ... Balloon dilatation of coronary sinus spasm during placement of a biventricular pacing lead. Circulation 2005; 111:e304-5. McKay ... Anterior myocardial infarction, acute aortic dissection and anomalous coronary artery. J Interven Cardiol 2002; 15:293-296. ...
*  Neointimal hyperplasia
... is the major cause of restenosis after percutaneous coronary interventions such as stenting or ... P radioactive β-emitting stents were used in coronary artery lesions with results showing inhibition of neointimal hyperplasia ... Shah, P.K. (2003). Inflammation, neointimal hyperplasia, and restenosis: as the leukocytes roll, the arteries thicken. ... Angioplasty Drug-eluting stent Restenosis Stent Kleinedler, J.J. (2012). Novel nanocomposite stent coating releasing ...
*  Sirolimus
The antiproliferative effect of sirolimus has also been used in conjunction with coronary stents to prevent restenosis in ... A sirolimus-eluting coronary stent was marketed by Cordis, a division of Johnson & Johnson, under the tradename Cypher. However ... "Cypher Sirolimus-eluting Coronary Stent". Cypher Stent. Retrieved 1 April 2008. Seto B (November 2012). "Rapamycin and mTOR: a ... Sirolimus, also known as rapamycin, is a macrolide compound that is used to coat coronary stents, prevent organ transplant ...
*  Brachytherapy
... can be used in the treatment of coronary in-stent restenosis, in which a catheter is placed inside blood vessels ... for the treatment of coronary in-stent restenosis. The dose rate of brachytherapy refers to the level or 'intensity' with which ... "Guidelines for Percutaneous Coronary Interventions: the Task Force for Percutaneous Coronary Interventions of the European ... In treating In-stent restenosis (ISR) Drug Eluting stents (DES) have been found to be superior to Intracoronary Brachytherapy ( ...
*  Phosphorylcholine
... to prevent the occurrence of coronary artery restenosis. The first application of this approach for use on stents evolved from ... This will dilate the diameter of the coronary artery and keep it fixed in this phase so that more blood flows through the ... Drug-eluting stents (DES) are used by interventional cardiologists, operating on patients with coronary artery disease. The ... Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation, Biomaterials 23 (2002), ...
*  Trapidil
Reduces Restenosis After Percutaneous Transluminal Coronary Angioplasty. Results of the Randomized, Double-Blind STARC Study". ...
*  Reviparin sodium
... and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary ... Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo- ... in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo- ... Prophylaxis of acute thrombotic events after percutaneous transluminal coronary angioplasty (PTCA) Kakkar VV, Cohen AT, Mohamed ...
*  Healthcare in Kosovo
... which is used for treatment of re-stenosis of coronary arteries. This is a breakthrough for Kosovo's medicine and the first ... Many of the newest treatments for coronary heart disease are performed within "Heart Hospital "EDA" through minimally invasive ... coronary artery stenting, ECG monitoring, and ECHO monitoring. Their doctors are currently participating at the worldwide ...
*  Stent
It was used as a scaffold to prevent the vessel from closing and to avoid restenosis in coronary surgery-a condition where scar ... The use of these bare-metal stents helped reduce the incidence of restenosis from 30-40% in coronary surgery to 20-30%.[ ... The first use of a coronary stent is typically attributed to Jacques Puel and Ulrich Sigwart when they implanted a stent into a ... As Ariel Roguin describes in his paper "Stent: The Man and Word Behind the Coronary Metal Prosthesis", the current acceptable ...
*  Everolimus
... is used in drug-eluting coronary stents as an immunosuppressant to prevent restenosis. Abbott Vascular produce an ...
*  Tranilast
... for prevention of restenosis after percutaneous transluminal coronary revascularization, but was not found effective for that ... "Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial" 2002 http://clinicaltrials.gov/ct2/show/ ...
*  Genous
The Genous Stent is a bio-engineered coronary stent coated with immobilized anti-CD34 monoclonal antibodies specific to the ... forming a functional endothelial layer over the stent to protect against thrombus and minimize restenosis. ... The Combo Dual Therapy Stent is a coronary stent that combines Genous with an antiproliferative, biodegradable sirolimus drug ...
*  Ticlopidine
"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis ... Ticlopidine is FDA approved for the prevention of strokes and, when combined with aspirin, for patients with a new coronary ... Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare ... 1996). "A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents". N ...